On August 13, 2025, a representative from BioTAG, a leading Israeli biotechnology product distributor, visited the Wuhan headquarters of AtaGenix (Pujian Biotech) for a day-long exchange and technical discussion. The visit aimed to explore collaboration potential in antibody drug development, protein engineering, and CRO services, fostering global innovation in precision medicine and biopharmaceuticals.

Fig.1. BioTAG Representative with AtaGenix Team

The BioTAG representative was warmly received and accompanied by AtaGenix co-founder Mr. Fubo Qin, General Manager Mr. Liang Lu, and other core team members.

During the visit, the BioTAG representative thoroughly inspected AtaGenix’s antibody discovery platform, protein expression laboratory, and quality control center, gaining detailed insights into the company’s technical advantages and successful cases in single B-cell antibody screening, antibody affinity optimization, recombinant protein production, and biopharmaceutical development services. The representative expressed high praise for AtaGenix’s expertise in high-throughput screening and customized R&D services.

Fig.2. BioTAG Representative Touring AtaGenix Experimental Platform

During the symposium, Mr. Fubo Qin introduced AtaGenix’s R&D progress in tumor immunology, autoimmune diseases, and infectious diseases, as well as its global biopharmaceutical collaboration network. General Manager Mr. Liang Lu added, “AtaGenix is committed to providing efficient, customized R&D solutions through technological innovation. We look forward to deepening our collaboration with BioTAG in antibody drug development and precision medicine to accelerate the development of innovative drugs.”

The BioTAG representative shared their core strengths in life sciences product distribution, cell culture material supply, and technical support services, expressing strong interest in collaborating with AtaGenix on joint R&D, technology transfer, and market expansion. Both parties engaged in in-depth discussions on future synergies in antibody drug development, preclinical research, and international projects.

This visit further strengthened mutual understanding and trust between AtaGenix and BioTAG, laying a solid foundation for their strategic collaboration in the biopharmaceutical field. AtaGenix will continue to uphold its mission of “connecting global biopharmaceutical innovation through technology,” working with global partners to advance the high-quality development of the biopharmaceutical industry and contribute to human health.

AtaGenix Company Profile

AtaGenix (Pujian Biotech) is a high-tech biotechnology company headquartered in Wuhan, China, specializing in antibody engineering, protein expression, and vaccine development services. The company boasts advanced platforms for single B-cell antibody screening, affinity maturation engineering, and eukaryotic protein expression systems, dedicated to providing high-quality CRO services globally. AtaGenix has extensive R&D efforts in infectious diseases, tumor immunology, and functional antibodies in vivo, establishing a collaborative network with numerous global research institutions and enterprises to drive biopharmaceutical innovation.

BioTAG Company Profile

Founded in 2011, BioTAG is an Israel-based biotechnology product distributor representing and distributing leading global life sciences products and services. The company supports various sectors of the Israeli industry, covering applications in cell culture, protein engineering and purification, molecular biology, signal transduction, cell biology, buffers and solutions, and immunoassay kits. BioTAG’s professional team, with over a decade of experience in sales, logistics, and technical support in the Israeli market, serves diverse clients, including pharmaceutical companies, academic institutions, biotech industries, and private laboratories, supporting life sciences research from startup to maturity. Currently, BioTAG is planning to establish a sales office in Europe to serve the European life sciences community, aiming to deliver high-quality, highly available, and competitively priced products globally.